[1]
Ruscio, A.M.; Stein, D.J.; Chiu, W.T.; Kessler, R.C. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol. Psychiatry, 2010, 15(1), 53-63. [http://dx.doi.org/10.1038/mp.2008.94]. [PMID: 18725912].
[2]
Olesen, J.; Gustavsson, A.; Svensson, M.; Wittchen, H.U.; Jönsson, B. The economic cost of brain disorders in Europe. Eur. J. Neurol., 2012, 19(1), 155-162. [http://dx.doi.org/10.1111/j.1468-1331.2011. 03590.x]. [PMID: 22175760].
[3]
Geller, D.A. Obsessive-compulsive and spectrum disorders in children and adolescents. Psychiatr. Clin. North Am., 2006, 29(2), 353-370. [http://dx.doi.org/10.1016/j.psc.2006.02.012]. [PMID: 16650713].
[4]
Kessler, R.C.; Berglund, P.; Demler, O.; Jin, R.; Merikangas, K.R.; Walters, E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry, 2005, 62(6), 593-602. [http://dx.doi. org/10.1001/archpsyc.62.6.593]. [PMID: 15939837].
[5]
Pallanti, S.; Quercioli, L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2006, 30(3), 400-412. [http://dx.doi.org/10.1016/j.pnpbp.2005. 11.028]. [PMID: 16503369].
[6]
Dell’Osso, B.; Benatti, B.; Hollander, E.; Fineberg, N.; Stein, D.J.; Lochner, C.; Nicolini, H.; Lanzagorta, N.; Palazzo, C.; Altamura, A.C.; Marazziti, D.; Pallanti, S.; Van Ameringen, M.; Karamustafalioglu, O.; Drummond, L.M.; Hranov, L.; Figee, M.; Grant, J.E.; Zohar, J.; Denys, D.; Menchon, J.M. Childhood, adolescent and adult age at onset and related clinical correlates in obsessive-compulsive disorder: A report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). Int. J. Psychiatry Clin. Pract., 2016, 20(4), 210-217. [http://dx.doi.org/10.1080/ 13651501.2016.1207087]. [PMID: 27433835].
[7]
Taylor, S. Early versus late onset obsessive-compulsive disorder: evidence for distinct subtypes. Clin. Psychol. Rev., 2011, 31(7), 1083-1100. [http://dx.doi.org/10.1016/j.cpr.2011.06.007]. [PMID: 21820387].
[8]
Grünblatt, E.; Oneda, B.; Ekici, A.B.; Ball, J.; Geissler, J.; Uebe, S.; Romanos, M.; Rauch, A.; Walitza, S. High resolution chromosomal microarray analysis in paediatric obsessive-compulsive disorder. BMC Med. Genomics, 2017, 10(1), 68. [http://dx.doi.org/ 10.1186/s12920-017-0299-5]. [PMID: 29179725].
[9]
Stewart, S.E.; Geller, D.A.; Jenike, M.; Pauls, D.; Shaw, D.; Mullin, B.; Faraone, S.V. Long-term outcome of pediatric obsessive-compulsive disorder: A meta-analysis and qualitative review of the literature. Acta Psychiatr. Scand., 2004, 110(1), 4-13. [http://dx. doi.org/10.1111/j.1600-0447.2004.00302.x]. [PMID: 15180774].
[10]
Fontenelle, L.F.; Mendlowicz, M.V.; Marques, C.; Versiani, M. Early- and late-onset obsessive-compulsive disorder in adult patients: an exploratory clinical and therapeutic study. J. Psychiatr. Res., 2003, 37(2), 127-133. [http://dx.doi.org/10.1016/S0022-3956(02)00087-0]. [PMID: 12842166].
[11]
Grover, S.; Sarkar, S.; Gupta, G.; Kate, N.; Ghosh, A.; Chakrabarti, S.; Avasthi, A. Factor analysis of symptom profile in early onset and late onset OCD. Psychiatry Res., 2017. [PMID: 29033063].
[12]
Delorme, R.; Bille, A.; Betancur, C.; Mathieu, F.; Chabane, N.; Mouren-Simeoni, M.C.; Leboyer, M. Exploratory analysis of obsessive compulsive symptom dimensions in children and adolescents: A prospective follow-up study. BMC Psychiatry, 2006, 6, 1. [http://dx.doi.org/10.1186/1471-244X-6-1]. [PMID: 16396684].
[13]
Boedhoe, P.S.; Schmaal, L.; Abe, Y.; Ameis, S.H.; Arnold, P.D.; Batistuzzo, M.C.; Benedetti, F.; Beucke, J.C.; Bollettini, I.; Bose, A.; Brem, S.; Calvo, A.; Cheng, Y.; Cho, K.I.; Dallaspezia, S.; Denys, D.; Fitzgerald, K.D.; Fouche, J.P.; Giménez, M.; Gruner, P.; Hanna, G.L.; Hibar, D.P.; Hoexter, M.Q.; Hu, H.; Huyser, C.; Ikari, K.; Jahanshad, N.; Kathmann, N.; Kaufmann, C.; Koch, K.; Kwon, J.S.; Lazaro, L.; Liu, Y.; Lochner, C.; Marsh, R.; Martínez-Zalacaín, I.; Mataix-Cols, D.; Menchón, J.M.; Minuzzi, L.; Nakamae, T.; Nakao, T.; Narayanaswamy, J.C.; Piras, F.; Piras, F.
Pittenger, C.; Reddy, Y.C.; Sato, J.R.; Simpson, H.B.; Soreni, N.; Soriano-Mas, C.; Spalletta, G.; Stevens, M.C.; Szeszko, P.R.; Tolin, D.F.; Venkatasubramanian, G.; Walitza, S.; Wang, Z.; van Wingen, G.A.; Xu, J.; Xu, X.; Yun, J.Y.; Zhao, Q.; Thompson, P.M.; Stein, D.J.; van den Heuvel, O.A.; van den Heuvel, O.A. Distinct Subcortical Volume Alterations in Pediatric and Adult OCD: A worldwide meta- and mega-analysis. Am. J. Psychiatry, 2017, 174(1), 60-69. [http://dx.doi.org/10.1176/appi.ajp.2016.16020201]. [PMID: 27609241].
[14]
Ivanov, I.; Bansal, R.; Hao, X.; Zhu, H.; Kellendonk, C.; Miller, L.; Sanchez-Pena, J.; Miller, A.M.; Chakravarty, M.M.; Klahr, K.; Durkin, K.; Greenhill, L.L.; Peterson, B.S. Morphological abnormalities of the thalamus in youths with attention deficit hyperactivity disorder. Am. J. Psychiatry, 2010, 167(4), 397-408. [http://dx. doi.org/10.1176/appi.ajp.2009.09030398]. [PMID: 20123910].
[15]
Miller, A.M.; Bansal, R.; Hao, X.; Sanchez-Pena, J.P.; Sobel, L.J.; Liu, J.; Xu, D.; Zhu, H.; Chakravarty, M.M.; Durkin, K.; Ivanov, I.; Plessen, K.J.; Kellendonk, C.B.; Peterson, B.S. Enlargement of thalamic nuclei in Tourette syndrome. Arch. Gen. Psychiatry, 2010, 67(9), 955-964. [http://dx.doi.org/10.1001/archgenpsychiatry.2010. 102]. [PMID: 20819989].
[16]
Gilbert, A.R.; Moore, G.J.; Keshavan, M.S.; Paulson, L.A.; Narula, V.; Mac Master, F.P.; Stewart, C.M.; Rosenberg, D.R. Decrease in thalamic volumes of pediatric patients with obsessive-compulsive disorder who are taking paroxetine. Arch. Gen. Psychiatry, 2000, 57(5), 449-456. [http://dx.doi.org/10.1001/archpsyc.57.5.449]. [PMID: 10807485].
[17]
Boileau, B. A review of obsessive-compulsive disorder in children and adolescents. Dialogues Clin. Neurosci., 2011, 13(4), 401-411. [PMID: 22275846].
[18]
Mataix-Cols, D.; Rosario-Campos, M.C.; Leckman, J.F. A multidimensional model of obsessive-compulsive disorder. Am. J. Psychiatry, 2005, 162(2), 228-238. [http://dx.doi.org/10.1176/appi. ajp.162.2.228]. [PMID: 15677583].
[19]
Alvarenga, P.G.; Cesar, R.C.; Leckman, J.F.; Moriyama, T.S.; Torres, A.R.; Bloch, M.H.; Coughlin, C.G.; Hoexter, M.Q.; Manfro, G.G.; Polanczyk, G.V.; Miguel, E.C.; do Rosario, M.C. Obsessive-compulsive symptom dimensions in a population-based, cross-sectional sample of school-aged children. J. Psychiatr. Res., 2015, 62, 108-114. [http://dx.doi.org/10.1016/j.jpsychires.2015.01.018]. [PMID: 25702286].
[20]
Fullana, M.A.; Mataix-Cols, D.; Caspi, A.; Harrington, H.; Grisham, J.R.; Moffitt, T.E.; Poulton, R. Obsessions and compulsions in the community: prevalence, interference, help-seeking, developmental stability, and co-occurring psychiatric conditions. Am. J. Psychiatry, 2009, 166(3), 329-336. [http://dx.doi.org/10.1176/ appi.ajp.2008.08071006]. [PMID: 19188283].
[21]
Alvarenga, P.G.; do Rosario, M.C.; Cesar, R.C.; Manfro, G.G.; Moriyama, T.S.; Bloch, M.H.; Shavitt, R.G.; Hoexter, M.Q.; Coughlin, C.G.; Leckman, J.F.; Miguel, E.C. Obsessive-compulsive symptoms are associated with psychiatric comorbidities, behavioral and clinical problems: A population-based study of Brazilian school children. Eur. Child Adolesc. Psychiatry, 2016, 25(2), 175-182. [http://dx.doi.org/10.1007/s00787-015-0723-3]. [PMID: 26015374].
[22]
Dell’Osso, B.; Camuri, G.; Benatti, B.; Buoli, M.; Altamura, A.C. Differences in latency to first pharmacological treatment (duration of untreated illness) in anxiety disorders: A study on patients with panic disorder, generalized anxiety disorder and obsessive-compulsive disorder. Early Interv. Psychiatry, 2013, 7(4), 374-380. [http://dx.doi.org/10.1111/eip.12016]. [PMID: 23347385].
[23]
Dell’Osso, B.; Buoli, M.; Hollander, E.; Altamura, A.C. Duration of untreated illness as a predictor of treatment response and remission in obsessive-compulsive disorder. World J. Biol. Psychiatry, 2010, 11(1), 59-65. [http://dx.doi.org/10.3109/15622970903418544]. [PMID: 20001657].
[24]
Mancebo, M.C.; Boisseau, C.L.; Garnaat, S.L.; Eisen, J.L.; Greenberg, B.D.; Sibrava, N.J.; Stout, R.L.; Rasmussen, S.A. Long-term course of pediatric obsessive-compulsive disorder: 3 years of prospective follow-up. Compr. Psychiatry, 2014, 55(7), 1498-1504. [http://dx.doi.org/10.1016/j.comppsych.2014.04.010]. [PMID: 24952937].
[25]
Melin, K.; Skarphedinsson, G.; Skärsäter, I.; Haugland, B.S.M.; Ivarsson, T. A solid majority remit following evidence-based OCD treatments: A 3-year naturalistic outcome study in pediatric OCD. Eur. Child Adolesc. Psychiatry, 2018. [http://dx.doi.org/10.1007/ s00787-018-1137-9]. [PMID: 29502315].
[26]
Hojgaard, D.; Hybel, K.A.; Ivarsson, T.; Skarphedinsson, G.; Becker Nissen, J.; Weidle, B.; Melin, K.; Torp, N.C.; Valderhaug, R.; Dahl, K.; Mortensen, E.L.; Compton, S.; Jensen, S.; Lenhard, F.; Thomsen, P.H. The relevance of analogue studies for understanding obsessions and compulsions. Clin. Psychol. Rev., 2014, 34(3), 206-217.
[27]
Abramowitz, J.S.; Fabricant, L.E.; Taylor, S.; Deacon, B.J.; McKay, D.; Storch, E.A. The relevance of analogue studies for understanding obsessions and compulsions. Clin. Psychol. Rev., 2014, 34(3), 206-217. [http://dx.doi.org/10.1016/j.cpr.2014.01.004]. [PMID: 24561743].
[28]
Zijlmans, J.; Marhe, R.; van der Ende, J.; Verhulst, F.C.; Popma, A.; Tiemeier, H.; van den Heuvel, O.A. Children with Obsessive-Compulsive Symptomology in the General Population: Different Subtypes? J. Dev. Behav. Pediatr., 2017, 38(7), 476-482. [http://dx. doi.org/10.1097/DBP.0000000000000467]. [PMID: 28691955].
[29]
de Mathis, M.A.; Diniz, J.B.; Hounie, A.G.; Shavitt, R.G.; Fossaluza, V.; Ferrão, Y.; Leckman, J.F.; de Bragança Pereira, C.; do Rosario, M.C.; Miguel, E.C. Trajectory in obsessive-compulsive disorder comorbidities. Eur. Neuropsychopharmacol., 2013, 23(7), 594-601. [http://dx.doi.org/10.1016/j.euroneuro.2012.08.006]. [PMID: 22921470].
[30]
Geller, D.A.; Biederman, J.; Faraone, S.V.; Bellordre, C.A.; Kim, G.S.; Hagermoser, L.; Cradock, K.; Frazier, J.; Coffey, B.J. Disentangling chronological age from age of onset in children and adolescents with obsessive-compulsive disorder. Int. J. Neuropsychopharmacol., 2001, 4(2), 169-178. [http://dx.doi.org/10.1017/ S1461145701002395]. [PMID: 11466167].
[31]
Selles, R.R.; Storch, E.A.; Lewin, A.B. Variations in symptom prevalence and clinical correlates in younger versus older youth with obsessive-compulsive disorder. Child Psychiatry Hum. Dev., 2014, 45(6), 666-674. [http://dx.doi.org/10.1007/s10578-014-0435-9]. [PMID: 24549726].
[32]
Abramovitch, A.; Dar, R.; Mittelman, A.; Wilhelm, S. Comorbidity between attention deficit/hyperactivity disorder and obsessive-compulsive disorder across the lifespan: A systematic and critical review. Harv. Rev. Psychiatry, 2015, 23(4), 245-262. [http:// dx.doi.org/10.1097/HRP.0000000000000050]. [PMID: 26052877].
[33]
Storch, E.A.; Merlo, L.J.; Larson, M.J.; Geffken, G.R.; Lehmkuhl, H.D.; Jacob, M.L.; Murphy, T.K.; Goodman, W.K. Impact of comorbidity on cognitive-behavioral therapy response in pediatric obsessive-compulsive disorder. J. Am. Acad. Child Adolesc. Psychiatry, 2008, 47(5), 583-592. [http://dx.doi.org/10.1097/CHI.0b013 e31816774b1]. [PMID: 18356759].
[34]
Guzick, A.G.; McNamara, J.P.H.; Reid, A.M.; Balkhi, A.M.; Storch, E.A.; Murphy, T.K.; Goodman, W.K.; Bussing, R.; Geffken, G.R. The link between ADHD-like inattention and obsessions and compulsions during treatment of youth with OCD. J. Obsessive Compuls. Relat. Disord., 2017, 12, 1-8. [http://dx.doi.org/10.1016/ j.jocrd.2016.11.004]. [PMID: 28966908].
[35]
Ivarsson, T.; Melin, K. Autism spectrum traits in children and adolescents with obsessive-compulsive disorder (OCD). J. Anxiety Disord., 2008, 22(6), 969-978. [http://dx.doi.org/10.1016/j.janxdis. 2007.10.003]. [PMID: 18053683].
[36]
Stewart, E.; Cancilliere, M.K.; Freeman, J.; Wellen, B.; Garcia, A.; Sapyta, J.; Franklin, M. Elevated autism spectrum disorder traits in young children with OCD. Child Psychiatry Hum. Dev., 2016, 47(6), 993-1001. [http://dx.doi.org/10.1007/s10578-016-0629-4]. [PMID: 26858231].
[37]
Tsuchiyagaito, A.; Hirano, Y.; Asano, K.; Oshima, F.; Nagaoka, S.; Takebayashi, Y.; Matsumoto, K.; Masuda, Y.; Iyo, M.; Shimizu, E.; Nakagawa, A. Cognitive-behavioral therapy for obsessive-compulsive disorder with and without autism spectrum disorder: Gray matter differences associated with poor outcome. Front. Psychiatry, 2017, 8, 143. [http://dx.doi.org/10.3389/fpsyt.2017.00143]. [PMID: 28861007].
[38]
Tanidir, C.; Adaletli, H.; Gunes, H.; Kilicoglu, A.G.; Mutlu, C.; Bahali, M.K.; Aytemiz, T.; Uneri, O.S. Impact of gender, age at onset, and lifetime tic disorders on the clinical presentation and comorbidity pattern of obsessive-compulsive disorder in children and adolescents. J. Child Adolesc. Psychopharmacol., 2015, 25(5), 425-431. [http://dx.doi.org/10.1089/cap.2014.0120]. [PMID: 26091196].
[39]
Conelea, C.A.; Walther, M.R.; Freeman, J.B.; Garcia, A.M.; Sapyta, J.; Khanna, M.; Franklin, M. Tic-related obsessive-compulsive disorder (OCD): phenomenology and treatment outcome in the Pediatric OCD Treatment Study II. J. Am. Acad. Child Adolesc. Psychiatry, 2014, 53(12), 1308-1316. [http://dx.doi.org/ 10.1016/j.jaac.2014.09.014]. [PMID: 25457929].
[40]
Ferrao, Y.A.D.; Alvarenga, P.G.; Hounie, A.G.; de Mathis, M.A.; de Rosario, M.C.; Miguel, E.C. The phenomenology of obsessive-compulsive symptoms in Tourette Syndrome.Oxford University Press. Vol. Tourette Syndrome, 2013.
[41]
Dell’Osso, B.; Marazziti, D.; Albert, U.; Pallanti, S.; Gambini, O.; Tundo, A.; Zanaboni, C.; Servello, D.; Rizzo, R.; Scalone, L.; Benatti, B.; Altamura, A.C.; Porta, M. Parsing the phenotype of obsessive-compulsive tic disorder (OCTD): a multidisciplinary consensus. Int. J. Psychiatry Clin. Pract., 2017, 21(2), 156-159. [http:// dx.doi.org/10.1080/13651501.2017.1291822]. [PMID: 28379724].
[42]
Skarphedinsson, G.; Compton, S.; Thomsen, P.H.; Weidle, B.; Dahl, K.; Nissen, J.B.; Torp, N.C.; Hybel, K.; Melin, K.H.; Valderhaug, R.; Wentzel-Larsen, T.; Ivarsson, T. Tics moderate sertraline, but not cognitive-behavior therapy response in pediatric obsessive-compulsive disorder patients who do not respond to cognitive-behavior therapy. J. Child Adolesc. Psychopharmacol., 2015, 25(5), 432-439. [http://dx.doi.org/10.1089/cap.2014.0167]. [PMID: 26091197].
[43]
March, J.S.; Franklin, M.E.; Leonard, H.; Garcia, A.; Moore, P.; Freeman, J.; Foa, E. Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder. Biol. Psychiatry, 2007, 61(3), 344-347. [http://dx.doi.org/10.1016/j.biopsych.2006.09.035]. [PMID: 17241830].
[44]
Pinto, R.; Monzani, B.; Leckman, J.F.; Rück, C.; Serlachius, E.; Lichtenstein, P.; Mataix-Cols, D. Understanding the covariation of tics, attention-deficit/hyperactivity, and obsessive-compulsive symptoms: A population-based adult twin study. Am. J. Med. Genet. B. Neuropsychiatr. Genet., 2016, 171(7), 938-947. [http:// dx.doi.org/10.1002/ajmg.b.32436]. [PMID: 26919823].
[45]
Turner, C.; O’Gorman, B.; Nair, A.; O’Kearney, R. Moderators and predictors of response to cognitive behaviour therapy for pediatric obsessive-compulsive disorder: A systematic review. Psychiatry Res., 2018, 261, 50-60. [http://dx.doi.org/10.1016/j.psychres.2017. 12.034]. [PMID: 29287236].
[46]
Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J. Am. Acad. Child Adolesc. Psychiatry, 2012, 51(1), 98-113. [http://dx.doi. org/10.1016/j.jaac.2011.09.019]. [PMID: 22176943].
[47]
National Collaborating Centre for Medical Health (UK).In Obsessive-Compulsive Disorder, core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder; Leicester, UK, 2006.
[48]
Varigonda, A.L.; Jakubovski, E.; Bloch, M.H. Systematic review and meta-analysis: Early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder. J. Am. Acad. Child Adolesc. Psychiatry, 2016, 55(10), 851-859.
[49]
London, A.; Cohen, M.; Schwartz, M. Microglia and monocyte-derived macrophages: Functionally distinct populations that act in concert in CNS plasticity and repair. Front. Cell. Neurosci., 2013, 7, 34. [http://dx.doi.org/10.3389/fncel.2013.00034]. [PMID: 23596391].
[50]
Swedo, S.E.; Rapoport, J.L.; Cheslow, D.L.; Leonard, H.L.; Ayoub, E.M.; Hosier, D.M.; Wald, E.R. High prevalence of obsessive-compulsive symptoms in patients with Sydenham’s chorea. Am. J. Psychiatry, 1989, 146(2), 246-249. [http://dx.doi.org/10.1176/ ajp.146.2.246]. [PMID: 2912267].
[51]
Swedo, S.E.; Leonard, H.L.; Garvey, M.; Mittleman, B.; Allen, A.J.; Perlmutter, S.; Lougee, L.; Dow, S.; Zamkoff, J.; Dubbert, B.K. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am. J. Psychiatry, 1998, 155(2), 264-271. [PMID: 9464208].
[52]
Swedo, S.E.L.J.; Rose, N.R. From Research Subgroup to Clinical Syndrome: Modifying the PANDAS Criteria to describe PANS (Pediatric Acute-onset Neuropsychiatric Syndrome). pediatr therapeut 2012.
[53]
Calaprice, D.; Tona, J.; Parker-Athill, E.C.; Murphy, T.K. A survey of pediatric acute-onset neuropsychiatric syndrome characteristics and course. J. Child Adolesc. Psychopharmacol., 2017, 27(7), 607-618. [PMID: 28140619].
[54]
Chiarello, F.; Spitoni, S.; Hollander, E.; Matucci Cerinic, M.; Pallanti, S. An expert opinion on PANDAS/PANS: Highlights and controversies. Int. J. Psychiatry Clin. Pract., 2017, 21(2), 91-98. [http:// dx.doi.org/10.1080/13651501.2017.1285941]. [PMID: 28498087].
[55]
Teixeira, A.L.; Rodrigues, D.H.; Marques, A.H.; Miguel, E.C.; Fontenelle, L.F. Searching for the immune basis of obsessive-compulsive disorder. Neuroimmunomodulation, 2014, 21(2-3), 152-158. [http://dx.doi.org/10.1159/000356554]. [PMID: 24557049].
[56]
Attwells, S.; Setiawan, E.; Wilson, A.A.; Rusjan, P.M.; Mizrahi, R.; Miler, L.; Xu, C.; Richter, M.A.; Kahn, A.; Kish, S.J.; Houle, S.; Ravindran, L.; Meyer, J.H. Inflammation in the neurocircuitry of obsessive-compulsive disorder. JAMA Psychiatry, 2017, 74(8), 833-840. [http://dx.doi.org/10.1001/jamapsychiatry.2017.1567]. [PMID: 28636705].
[57]
Réus, G.Z.; Fries, G.R.; Stertz, L.; Badawy, M.; Passos, I.C.; Barichello, T.; Kapczinski, F.; Quevedo, J. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience, 2015, 300, 141-154. [http://dx.doi.org/ 10.1016/j.neuroscience.2015.05.018]. [PMID: 25981208].
[58]
Frick, L.R.; Williams, K.; Pittenger, C. Microglial dysregulation in psychiatric disease. Clin. Dev. Immunol., 2013, 2013608654 [http://dx.doi.org/10.1155/2013/608654]. [PMID: 23690824].
[59]
Amantea, D.; Bagetta, G. Drug repurposing for immune modulation in acute ischemic stroke. Curr. Opin. Pharmacol., 2016, 26, 124-130. [http://dx.doi.org/10.1016/j.coph.2015.11.006]. [PMID: 26657075].
[60]
Burchi, E.P.S. Antibiotics for PANDAS? Limited evidence. Review and putative mechanisms of action. Prim Care Companion CNS, in press
[61]
Stock, M.L.; Fiedler, K.J.; Acharya, S.; Lange, J.K.; Mlynarczyk, G.S.; Anderson, S.J.; McCormack, G.R.; Kanuri, S.H.; Kondru, N.C.; Brewer, M.T.; Carlson, S.A. Antibiotics acting as neuroprotectants via mechanisms independent of their anti-infective activities. Neuropharmacology, 2013, 73, 174-182. [http://dx.doi.org/ 10.1016/j.neuropharm.2013.04.059]. [PMID: 23748053].
[62]
Rothstein, J.D.; Patel, S.; Regan, M.R.; Haenggeli, C.; Huang, Y.H.; Bergles, D.E.; Jin, L.; Dykes Hoberg, M.; Vidensky, S.; Chung, D.S.; Toan, S.V.; Bruijn, L.I.; Su, Z.Z.; Gupta, P.; Fisher, P.B. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature, 2005, 433(7021), 73-77. [http://dx.doi.org/10.1038/nature03180]. [PMID: 15635412].
[63]
Shmelkov, S.V.; Hormigo, A.; Jing, D.; Proenca, C.C.; Bath, K.G.; Milde, T.; Shmelkov, E.; Kushner, J.S.; Baljevic, M.; Dincheva, I.; Murphy, A.J.; Valenzuela, D.M.; Gale, N.W.; Yancopoulos, G.D.; Ninan, I.; Lee, F.S.; Rafii, S. Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. Nat. Med., 2010, 16(5), 598-602. [http://dx. doi.org/10.1038/nm.2125].
[64]
Welch, J.M.; Lu, J.; Rodriguiz, R.M.; Trotta, N.C.; Peca, J.; Ding, J.D.; Feliciano, C.; Chen, M.; Adams, J.P.; Luo, J.; Dudek, S.M.; Weinberg, R.J.; Calakos, N.; Wetsel, W.C.; Feng, G. Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature, 2007, 448(7156), 894-900. [http://dx.doi.org/ 10.1038/nature06104]. [PMID: 17713528].
[65]
Stewart, S.E.; Mayerfeld, C.; Arnold, P.D.; Crane, J.R.; O’Dushlaine, C.; Fagerness, J.A.; Yu, D.; Scharf, J.M.; Chan, E.; Kassam, F.; Moya, P.R.; Wendland, J.R.; Delorme, R.; Richter, M.A.; Kennedy, J.L.; Veenstra-VanderWeele, J.; Samuels, J.; Greenberg, B.D.; McCracken, J.T.; Knowles, J.A.; Fyer, A.J.; Rauch, S.L.; Riddle, M.A.; Grados, M.A.; Bienvenu, O.J.; Cullen, B.; Wang, Y.; Shugart, Y.Y.; Piacentini, J.; Rasmussen, S.; Nestadt, G.; Murphy, D.L.; Jenike, M.A.; Cook, E.H.; Pauls, D.L.; Hanna, G.L.; Mathews, C.A. Meta-analysis of association between obsessive-compulsive disorder and the 3′ region of neuronal glutamate transporter gene SLC1A1. Am. J. Med. Genet. B. Neuropsychiatr. Genet., 2013, 162B(4), 367-379. [http://dx.doi.org/10.1002/ajmg.b. 32137]. [PMID: 23606572].
[66]
Alonso, P.; Gratacós, M.; Segalàs, C.; Escaramís, G.; Real, E.; Bayés, M.; Labad, J.; López-Solà, C.; Estivill, X.; Menchón, J.M. Association between the NMDA glutamate receptor GRIN2B gene and obsessive-compulsive disorder. J. Psychiatry Neurosci., 2012, 37(4), 273-281. [http://dx.doi.org/10.1503/jpn.110109]. [PMID: 22433450].
[67]
Hirschtritt, M.E.; Bloch, M.H.; Mathews, C.A. Obsessive-compulsive disorder: Advances in diagnosis and treatment. JAMA, 2017, 317(13), 1358-1367. [http://dx.doi.org/10.1001/jama. 2017.2200]. [PMID: 28384832].
[68]
Laoutidis, Z.G.; Lekka, G.E.; Kioulos, K.T. Glutamatergic agents as add-on medication for the treatment of obsessive-compulsive disorder: A systematic review and meta-analysis. J. Clin. Psychiatry, 2016, 77(12), e1576-e1583. [http://dx.doi.org/10.4088/ JCP.15r10164]. [PMID: 27780337].
[69]
O’Neill, J.; Piacentini, J.; Chang, S.; Ly, R.; Lai, T.M.; Armstrong, C.C.; Bergman, L.; Rozenman, M.; Peris, T.; Vreeland, A.; Mudgway, R.; Levitt, J.G.; Salamon, N.; Posse, S.; Hellemann, G.S.; Alger, J.R.; McCracken, J.T.; Nurmi, E.L. Glutamate in pediatric obsessive-compulsive disorder and response to cognitive-behavioral therapy: Randomized clinical triaL. Neuropsychopharmacology, 2017, 42(12), 2414-2422. [http://dx.doi.org/10.1038/npp.2017.77]. [PMID: 28409563].
[70]
Grant, P.J.; Joseph, L.A.; Farmer, C.A.; Luckenbaugh, D.A.; Lougee, L.C.; Zarate, C.A., Jr; Swedo, S.E. 12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder. Neuropsychopharmacology, 2014, 39(6), 1453-1459. [http://dx.doi.org/10.1038/npp.2013.343]. [PMID: 24356715].
[71]
Storch, E.A.; Wilhelm, S.; Sprich, S.; Henin, A.; Micco, J.; Small, B.J.; McGuire, J.; Mutch, P.J.; Lewin, A.B.; Murphy, T.K.; Geller, D.A. Efficacy of augmentation of cognitive behavior therapy with weight-adjusted d-cycloserine vs. placebo in pediatric obsessive-compulsive disorder: A randomized clinical trial. JAMA Psychiatry, 2016, 73(8), 779-788. [http://dx.doi.org/10.1001/jamapsychiatry. 2016.1128]. [PMID: 27367832].
[72]
Ghanizadeh, A.; Mohammadi, M.R.; Bahraini, S.; Keshavarzi, Z.; Firoozabadi, A.; Alavi Shoshtari, A. Efficacy of N-acetylcysteine augmentation on obsessive compulsive disorder: A multicenter randomized double blind placebo controlled clinical trial. Iran. J. Psychiatry, 2017, 12(2), 134-141. [PMID: 28659986].
[73]
Mechler, K.; Häge, A.; Schweinfurth, N.; Glennon, J.C.; Dijkhuizen, R.M.; Murphy, D.; Durston, S.; Williams, S.; Buitelaar, J.K.; Banaschewski, T.; Dittmann, R.W. Tactics Consortium. T. Glutamatergic agents in the treatment of compulsivity and impulsivity in child and adolescent psychiatry: A systematic review of the literature. Z. Kinder Jugendpsychiatr. Psychother., 2018, 46(3), 246-263. [http://dx.doi.org/10.1024/1422-4917/a000546]. [PMID: 28922069].
[74]
Pasquini, M.; Biondi, M. Memantine augmentation for refractory obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2006, 30(6), 1173-1175. [http://dx.doi.org/10. 1016/j.pnpbp.2006.04.013]. [PMID: 16730870].
[75]
Rodriguez, C.I.; Bender, J., Jr; Marcus, S.M.; Snape, M.; Rynn, M.; Simpson, H.B. Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial. J. Clin. Psychiatry, 2010, 71(9), 1247-1249. [http://dx.doi.org/10.4088/JCP. 09l05805blu]. [PMID: 20923629].
[76]
Dean, O.M.; Data-Franco, J.; Giorlando, F.; Berk, M. Minocycline: therapeutic potential in psychiatry. CNS Drugs, 2012, 26(5), 391-401. [http://dx.doi.org/10.2165/11632000-000000000-00000]. [PMID: 22486246].
[77]
Chakrabarty, K.; Bhattacharyya, S.; Christopher, R.; Khanna, S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology, 2005, 30(9), 1735-1740. [http://dx.doi.org/10.1038/sj.npp.1300733]. [PMID: 15841109].
[78]
Rao, N.P.; Venkatasubramanian, G.; Ravi, V.; Kalmady, S.; Cherian, A.; Yc, J.R. Plasma cytokine abnormalities in drug-naïve, comorbidity-free obsessive-compulsive disorder. Psychiatry Res., 2015, 229(3), 949-952. [http://dx.doi.org/10.1016/j.psychres. 2015.07.009]. [PMID: 26187339].
[79]
Çolak Sivri, R.; Bilgiç, A.; Kılınç, İ. Cytokine, chemokine and BDNF levels in medication-free pediatric patients with obsessive-compulsive disorder. Eur. Child Adolesc. Psychiatry, 2018. [PMID: 29302747].
[80]
Rodríguez, N.; Morer, A.; González-Navarro, E.A.; Serra-Pages, C.; Boloc, D.; Torres, T.; García-Cerro, S.; Mas, S.; Gassó, P.; Lázaro, L. Inflammatory dysregulation of monocytes in pediatric patients with obsessive-compulsive disorder. J. Neuroinflammation, 2017, 14(1), 261. [http://dx.doi.org/10.1186/s12974-017-1042-z]. [PMID: 29284508].
[81]
Nazimek, K.; Strobel, S.; Bryniarski, P.; Kozlowski, M.; Filipczak-Bryniarska, I.; Bryniarski, K. The role of macrophages in anti-inflammatory activity of antidepressant drugs. Immunobiology, 2017, 222(6), 823-830. [http://dx.doi.org/10.1016/j.imbio.2016.07. 001]. [PMID: 27453459].
[82]
Gobin, V.; Van Steendam, K.; Denys, D.; Deforce, D. Selective serotonin reuptake inhibitors as a novel class of immunosuppressants. Int. Immunopharmacol., 2014, 20(1), 148-156. [http://dx.doi. org/10.1016/j.intimp.2014.02.030]. [PMID: 24613205].
[83]
Gałecki, P.; Mossakowska-Wójcik, J.; Talarowska, M. The anti-inflammatory mechanism of antidepressants - SSRIs, SNRIs. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2018, 80(Pt C), 291-294. [http://dx.doi.org/10.1016/j.pnpbp.2017.03.016]. [PMID: 28342944].
[84]
Alboni, S.; Poggini, S.; Garofalo, S.; Milior, G.; El Hajj, H.; Lecours, C.; Girard, I.; Gagnon, S.; Boisjoly-Villeneuve, S.; Brunello, N.; Wolfer, D.P.; Limatola, C.; Tremblay, M.E.; Maggi, L.; Branchi, I. Fluoxetine treatment affects the inflammatory response and microglial function according to the quality of the living environment. Brain Behav. Immun., 2016, 58, 261-271. [http://dx.doi. org/10.1016/j.bbi.2016.07.155]. [PMID: 27474084].
[85]
Sun, Y.; Narayan, V.A.; Wittenberg, G.M. Side effect profile similarities shared between antidepressants and immune-modulators reveal potential novel targets for treating major depressive disorders. BMC Pharmacol. Toxicol., 2016, 17(1), 47. [http://dx.doi.org/ 10.1186/s40360-016-0090-9]. [PMID: 27765060].
[86]
Sayyah, M.; Boostani, H.; Pakseresht, S.; Malayeri, A. A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder. Psychiatry Res., 2011, 189(3), 403-406. [http://dx.doi.org/ 10.1016/j.psychres.2011.01.019]. [PMID: 21329988].
[87]
Shalbafan, M.; Mohammadinejad, P.; Shariat, S.V.; Alavi, K.; Zeinoddini, A.; Salehi, M.; Askari, N.; Akhondzadeh, S. Celecoxib as an adjuvant to fluvoxamine in moderate to severe obsessive-compulsive disorder: A double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry, 2015, 48(4-5), 136-140. [PMID: 25959196].
[88]
Strauss, K.I.; Marini, A.M. Cyclooxygenase-2 inhibition protects cultured cerebellar granule neurons from glutamate-mediated cell death. J. Neurotrauma, 2002, 19(5), 627-638. [http://dx.doi.org/ 10.1089/089771502753754091]. [PMID: 12042097].
[89]
Borre, Y.E.; Moloney, R.D.; Clarke, G.; Dinan, T.G.; Cryan, J.F. The impact of microbiota on brain and behavior: Mechanisms & therapeutic potential. Adv. Exp. Med. Biol., 2014, 817, 373-403. [http://dx.doi.org/10.1007/978-1-4939-0897-4_17]. [PMID: 24997043].
[90]
Cenit, M.C.; Sanz, Y.; Codoñer-Franch, P. Influence of gut microbiota on neuropsychiatric disorders. World J. Gastroenterol., 2017, 23(30), 5486-5498. [http://dx.doi.org/10.3748/wjg.v23.i30.5486]. [PMID: 28852308].
[91]
Burokas, A.; Arboleya, S.; Moloney, R.D.; Peterson, V.L.; Murphy, K.; Clarke, G.; Stanton, C.; Dinan, T.G.; Cryan, J.F. Targeting the microbiota-gut-brain axis: Prebiotics have anxiolytic and antidepressant-like effects and reverse the impact of chronic stress in mice. Biol. Psychiatry, 2017, 82(7), 472-487. [http:// dx.doi.org/10.1016/j.biopsych.2016.12.031]. [PMID: 28242013].
[92]
Turna, J.; Grosman, K.K.; Anglin, R.; Van Ameringen, M. “What’s bugging the gut in Ocd?” a review of the gut microbiome in obsessive-compulsive disorder. Depress. Anxiety, 2016, 33(3), 171-178. [http://dx.doi.org/10.1002/da.22454]. [PMID: 26629974].
[93]
Kantak, P.A.; Bobrow, D.N.; Nyby, J.G. Obsessive-compulsive-like behaviors in house mice are attenuated by a probiotic (Lactobacillus rhamnosus GG). Behav. Pharmacol., 2014, 25(1), 71-79. [http://dx.doi.org/10.1097/FBP.0000000000000013]. [PMID: 24257436].
[94]
Insel, T.; Cuthbert, B.; Garvey, M.; Heinssen, R.; Pine, D.S.; Quinn, K.; Sanislow, C.; Wang, P. Research domain criteria (RDoC): Toward a new classification framework for research on mental disorders. Am. J. Psychiatry, 2010, 167(7), 748-751. [http:// dx.doi.org/10.1176/appi.ajp.2010.09091379]. [PMID: 20595427].
[95]
Valentin, V.V.; Dickinson, A.; O’Doherty, J.P. Determining the neural substrates of goal-directed learning in the human brain. J. Neurosci., 2007, 27(15), 4019-4026. [http://dx.doi.org/10.1523/ JNEUROSCI.0564-07.2007]. [PMID: 17428979].
[96]
Ahmari, S.E.; Dougherty, D.D. Dissecting Ocd Circuits: From animal models to targeted treatments. Depress. Anxiety, 2015, 32(8), 550-562. [http://dx.doi.org/10.1002/da.22367]. [PMID: 25952989].
[97]
Brennan, B. Use of an Individual-Level Approach to Identify Cortical
Connectivity Biomarkers of Global and Dimen- sional Symptom
Severity and Improvement in Obsessive-Compulsive Disorder.
ACNP 56th Annual Meeting, Poster session.
